Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
HMP.TO 0.03SPGP 1ZUQ.TO 0.55NVDA 0.32GL 1.66MRK -1.71IEMG 0.5GEV 33.87
Novelion (NVLN.TO)
The ultimate 360° Tracker Your financial life in one place, automatically

Novelion (NVLN.TO)

0.00
-0.00 (0.00%)
52 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
BUY

Novelion(NVLN.TO)

Mar 31, 2004
Great story. Shares are fully priced. Dont own
Photo of Peter BriegerPeter Brieger
No
Unlock Rating
$33.28

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY ON WEAKNESS

Novelion(NVLN.TO)

Mar 25, 2004
Likes the company, but is waiting for the price to pull back into the $20's before buying it again.
Photo of Robert FloydRobert Floyd
No
Unlock Rating
$32.17

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Novelion(NVLN.TO)

Mar 04, 2004
Have had drug developments that have been going a lot better for them. Prefers biotech companies that have a broader product mix. Market outlook seems to be quite positive for them.
Photo of Michael SprungMichael Sprung
No
Unlock Rating
$32.28

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Novelion(NVLN.TO)

Feb 17, 2004
Visudine is approved for macular degeneration as well as ocular degeneration. Now making lots of money.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$31.24

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Novelion(NVLN.TO)

Feb 03, 2004
Own. Great technology. A lot to go. May have a bit of a pullback
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$33.00

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Jan 22, 2004
Have had difficulty in getting broad exposure of their products in the US. The jury is still out on whether this is a long-term efficacious treatment or not.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$24.10

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Novelion(NVLN.TO)

Jan 20, 2004
The long-term outlook should be good based on their product or vision health.
Photo of Peter BriegerPeter BriegerUnlock Rating
$22.51

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY ON WEAKNESS

Novelion(NVLN.TO)

Jan 08, 2004
Thinks are still a little bit of upside. Potential for growth. Would buy on weakness.
Photo of Mark Jackson, CFAMark Jackson, CFA
Owned
Unlock Rating
$25.62

Stock price when the opinion was issued

biotechnologypharmaceutical
WEAK BUY

Novelion(NVLN.TO)

Dec 22, 2003
Expects the growth from visudine will be very strong. Buy for a three-year hold.
Photo of Peter BriegerPeter Brieger
No
Unlock Rating
$24.80

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Dec 17, 2003
Model price is $24.83, so fully valued. Would consider at $21.40.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$24.52

Stock price when the opinion was issued

biotechnologypharmaceutical
PAST TOP PICK

Novelion(NVLN.TO)

Dec 16, 2003
(A past top pick Sept 23/03. Up 5%.) Still likes. Has been volatile. Continue to believe in Visudine and the improved use of it.
Photo of Ted MacklinTed Macklin
Owned
Unlock Rating
$24.60

Stock price when the opinion was issued

biotechnologypharmaceutical
TOP PICK

Novelion(NVLN.TO)

Nov 13, 2003
Suspects the price may mistakenly drop because of competitor coming out with a drug, but it will actually be used with QLT’s. Have had good earnings. The multiple in the high teens is really attractive. Have cash. Volatile
Photo of John ZechnerJohn Zechner
Owned
Unlock Rating
$20.29

Stock price when the opinion was issued

biotechnologypharmaceutical
HOLD

Novelion(NVLN.TO)

Oct 30, 2003
A very volatile stock. The caveat is that it is a one trick pony. Healthcare stocks have pulled back quite a bit.
Photo of Ted MacklinTed Macklin
Owned
Unlock Rating
$20.37

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Oct 28, 2003
Have had good news recently in that their treatment for eye disease has been accepted by a number of US insurance companies. Probably fully priced now.
Photo of David BaskinDavid BaskinUnlock Rating
$20.70

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Oct 02, 2003
There have been a few negative developments this year. Fully valued.
Photo of John ZechnerJohn Zechner
No
Unlock Rating
$21.94

Stock price when the opinion was issued

biotechnologypharmaceutical
Showing 46 to 60 of 190 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EPD -0.03$37.25
ET 0.31$19.07
MAIR 0$
RKLB -12.39$102.39
SESG-O 0$

Today's Top Picks

HMP.TO 0.03$9.75
SPGP 1$120.39
ZUQ.TO 0.55$107.47
NVDA 0.32$205.19
GL 1.66$166.76

Popular Articles

Latest Sell Signals

PRGO 0.09$10.99
CBRS 0$
HAWK 0$
AVEX 0$
SWMR 0$

Most Recent Experts

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Richard Orrell

Richard Orrell

RN Croft Financial Group

Stockchase Insights

Stockchase Insights

5i Research

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stan Wong

Stan Wong

Private Wealth Management, ScotiaMcleod

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica